Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease

NCT06293365 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

155

Enrollment

INDUSTRY

Sponsor class

Conditions

Sjögrens Disease
Systemic Lupus Erythematosus
Rheumatoid Arthritis

Interventions

BIOLOGICAL: VAY736 1ml PFS
BIOLOGICAL: VAY736 2 ml PFS
BIOLOGICAL: VAY736 2ml AI

Sponsor

Novartis Pharmaceuticals